Drug intelligence / Profile preview

WC-DF-3206

Development stage: Preclinical
Lead developer: 福建博悦医药科技
Modality: Small Molecules

Overview

WC-DF-3206 is a preclinical-stage small molecule inhibitor targeting cyclin-dependent kinases 4 and 6 (CDK4/6). Developed by Fujian Boyue Pharmaceutical Technology, a subsidiary of Shanghai Boyue Biotechnology, the compound is being investigated for the treatment of various cancers. By selectively inhibiting CDK4 and CDK6, WC-DF-3206 aims to block the phosphorylation of retinoblastoma protein (Rb), thereby arresting the cell cycle at the G1/S transition and suppressing tumor cell proliferation.

Targets

CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)

Beyond the preview

Go deeper on WC-DF-3206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WC-DF-3206.